Edwards Lifesciences Corp【EW】Cash flow
Market cap
$49.9B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 57 | 58 | 57 | 69 | 69 | 66 | 71 | 82 | 77 | 89 | 107 | 135 | 140 | 145 | 155 |
| Stock-based compensation | 29 | 35 | 42 | 47 | 48 | 50 | 57 | 62 | 71 | 81 | 93 | 109 | 127 | 139 | 162 |
| Cash from operations | 251 | 315 | 374 | 473 | 1,022 | 550 | 704 | 1,001 | 927 | 1,179 | 1,054 | 1,732 | 1,218 | 896 | 542 |
| Capital expenditures | -62 | -83 | -121 | -109 | -83 | -103 | -176 | -168 | -239 | -254 | -407 | -326 | -245 | -253 | -252 |
| Cash from investing | -61 | -413 | -90 | -413 | -633 | -316 | -212 | -647 | 77 | -596 | -531 | -1,722 | 252 | 174 | 2,313 |
| Repurchases of common stock | 200 | 303 | 344 | 497 | 301 | 280 | 662 | 763 | 796 | 263 | 625 | 513 | 1,727 | 880 | 1,159 |
| Proceeds from issuance of term debt, net | - | - | - | 1,305 | 226 | 31 | 254 | 995 | 688 | 19 | 16 | 5 | - | - | - |
| Repayments of term debt | - | - | - | 895 | - | - | - | - | - | - | - | - | - | - | - |
| Cash from financing | -104 | -135 | -156 | 35 | -153 | -159 | -268 | -473 | -1,101 | -116 | -487 | -356 | -1,584 | -711 | -983 |
| Free cash flow | |||||||||||||||
| FCF margin (%) |